HRP20250204T1 - Tablete za oralno otapanje - Google Patents
Tablete za oralno otapanje Download PDFInfo
- Publication number
- HRP20250204T1 HRP20250204T1 HRP20250204TT HRP20250204T HRP20250204T1 HR P20250204 T1 HRP20250204 T1 HR P20250204T1 HR P20250204T T HRP20250204T T HR P20250204TT HR P20250204 T HRP20250204 T HR P20250204T HR P20250204 T1 HRP20250204 T1 HR P20250204T1
- Authority
- HR
- Croatia
- Prior art keywords
- tablet
- weight
- propylthio
- triazolo
- hydroxyethoxy
- Prior art date
Links
- OEKWJQXRCDYSHL-FNOIDJSQSA-N ticagrelor Chemical compound C1([C@@H]2C[C@H]2NC=2N=C(N=C3N([C@H]4[C@@H]([C@H](O)[C@@H](OCCO)C4)O)N=NC3=2)SCCC)=CC=C(F)C(F)=C1 OEKWJQXRCDYSHL-FNOIDJSQSA-N 0.000 claims 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims 4
- 230000007214 atherothrombosis Effects 0.000 claims 2
- 208000010125 myocardial infarction Diseases 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 2
- 239000000377 silicon dioxide Substances 0.000 claims 2
- 208000004476 Acute Coronary Syndrome Diseases 0.000 claims 1
- 208000024172 Cardiovascular disease Diseases 0.000 claims 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 1
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims 1
- 229930195725 Mannitol Natural products 0.000 claims 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims 1
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims 1
- 208000005764 Peripheral Arterial Disease Diseases 0.000 claims 1
- 208000030831 Peripheral arterial occlusive disease Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- 208000007536 Thrombosis Diseases 0.000 claims 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 claims 1
- 229960000913 crospovidone Drugs 0.000 claims 1
- VCVOSERVUCJNPR-UHFFFAOYSA-N cyclopentane-1,2-diol Chemical compound OC1CCCC1O VCVOSERVUCJNPR-UHFFFAOYSA-N 0.000 claims 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims 1
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 239000000594 mannitol Substances 0.000 claims 1
- 235000010355 mannitol Nutrition 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims 1
- 239000008108 microcrystalline cellulose Substances 0.000 claims 1
- 229940016286 microcrystalline cellulose Drugs 0.000 claims 1
- 235000013809 polyvinylpolypyrrolidone Nutrition 0.000 claims 1
- 229920000523 polyvinylpolypyrrolidone Polymers 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 235000012239 silicon dioxide Nutrition 0.000 claims 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 claims 1
- 208000023516 stroke disease Diseases 0.000 claims 1
- 239000000811 xylitol Substances 0.000 claims 1
- 235000010447 xylitol Nutrition 0.000 claims 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims 1
- 229960002675 xylitol Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
- A61J1/035—Blister-type containers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
- A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B65—CONVEYING; PACKING; STORING; HANDLING THIN OR FILAMENTARY MATERIAL
- B65D—CONTAINERS FOR STORAGE OR TRANSPORT OF ARTICLES OR MATERIALS, e.g. BAGS, BARRELS, BOTTLES, BOXES, CANS, CARTONS, CRATES, DRUMS, JARS, TANKS, HOPPERS, FORWARDING CONTAINERS; ACCESSORIES, CLOSURES, OR FITTINGS THEREFOR; PACKAGING ELEMENTS; PACKAGES
- B65D75/00—Packages comprising articles or materials partially or wholly enclosed in strips, sheets, blanks, tubes or webs of flexible sheet material, e.g. in folded wrappers
- B65D75/28—Articles or materials wholly enclosed in composite wrappers, i.e. wrappers formed by associating or interconnecting two or more sheets or blanks
- B65D75/30—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding
- B65D75/32—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents
- B65D75/325—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil
- B65D75/327—Articles or materials enclosed between two opposed sheets or blanks having their margins united, e.g. by pressure-sensitive adhesive, crimping, heat-sealing, or welding one or both sheets or blanks being recessed to accommodate contents one sheet being recessed, and the other being a flat not- rigid sheet, e.g. puncturable or peelable foil and forming several compartments
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Composite Materials (AREA)
- Mechanical Engineering (AREA)
- Zoology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Diabetes (AREA)
- Vascular Medicine (AREA)
- Hematology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medical Preparation Storing Or Oral Administration Devices (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662325584P | 2016-04-21 | 2016-04-21 | |
| EP17720055.7A EP3445338B1 (en) | 2016-04-21 | 2017-04-20 | Orally disintegrating tablets |
| PCT/EP2017/059443 WO2017182589A1 (en) | 2016-04-21 | 2017-04-20 | Orally disintegrating tablets |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20250204T1 true HRP20250204T1 (hr) | 2025-04-11 |
Family
ID=58640851
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20250204TT HRP20250204T1 (hr) | 2016-04-21 | 2017-04-20 | Tablete za oralno otapanje |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US10729655B2 (enExample) |
| EP (2) | EP4417537A3 (enExample) |
| JP (2) | JP6960941B2 (enExample) |
| KR (2) | KR102392347B1 (enExample) |
| CN (3) | CN107595789B (enExample) |
| AU (2) | AU2017253367B2 (enExample) |
| BR (1) | BR112018071440A2 (enExample) |
| CO (1) | CO2018012431A2 (enExample) |
| DK (1) | DK3445338T3 (enExample) |
| EA (1) | EA201892150A1 (enExample) |
| ES (1) | ES3014055T3 (enExample) |
| FI (1) | FI3445338T3 (enExample) |
| HR (1) | HRP20250204T1 (enExample) |
| HU (1) | HUE070095T2 (enExample) |
| IL (1) | IL262312B (enExample) |
| LT (1) | LT3445338T (enExample) |
| MA (1) | MA44720B1 (enExample) |
| PE (1) | PE20190372A1 (enExample) |
| PH (1) | PH12018502226A1 (enExample) |
| PL (1) | PL3445338T3 (enExample) |
| PT (1) | PT3445338T (enExample) |
| RS (1) | RS66536B1 (enExample) |
| SG (2) | SG10202107682QA (enExample) |
| SI (1) | SI3445338T1 (enExample) |
| SM (1) | SMT202500081T1 (enExample) |
| WO (1) | WO2017182589A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111450067A (zh) * | 2019-01-18 | 2020-07-28 | 北京万全德众医药生物技术有限公司 | 一种替格瑞洛分散片及其制备方法 |
| CN109700773B (zh) * | 2019-03-01 | 2021-03-16 | 石药集团中奇制药技术（石家庄）有限公司 | 一种替格瑞洛制剂组合物及其制备方法 |
| JP7657041B2 (ja) | 2020-08-19 | 2025-04-04 | アストラゼネカ・アクチエボラーグ | 併用療法 |
| CN114712317A (zh) * | 2021-01-04 | 2022-07-08 | 弘和制药有限公司 | 一种替格瑞洛药物组合物及其制备方法和其应用 |
| US20220387328A1 (en) * | 2021-06-04 | 2022-12-08 | Glaxosmithkline Consumer Healthcare Holdings (Us) Llc | Dosage form for nicotine replacement therapy |
| WO2023057879A1 (en) * | 2021-10-04 | 2023-04-13 | Neurim Pharmaceuticals (1991) Ltd. | Methods and products for treating subjects with autism spectrum disorders |
| CN120129530A (zh) | 2022-10-28 | 2025-06-10 | 阿斯利康(瑞典)有限公司 | 以40mg至240mg的剂量用于在治疗缺血事件中使用的重组腺苷三磷酸双磷酸酶蛋白 |
| CN116370423B (zh) * | 2023-02-28 | 2024-11-12 | 天津力生制药股份有限公司 | 一种替格瑞洛口腔崩解片及其制备方法 |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB516834A (en) * | 1937-12-23 | 1940-01-12 | Charles Alexandre Nicolle | Improvements in or relating to packaging |
| DE2246013A1 (de) | 1972-09-20 | 1974-03-28 | Boehringer Mannheim Gmbh | Verfahren zur herstellung von poroesen tabletten |
| TWI229674B (en) | 1998-12-04 | 2005-03-21 | Astra Pharma Prod | Novel triazolo[4,5-d]pyrimidine compounds, pharmaceutical composition containing the same, their process for preparation and uses |
| GB0013407D0 (en) | 2000-06-02 | 2000-07-26 | Astrazeneca Ab | Forms of a chemical compound |
| ES2268020T3 (es) * | 2001-05-10 | 2007-03-16 | Astellas Pharma Inc. | Comprimidos de disgregacion rapida de la cavidad oral y proceso para producir los mismos. |
| US7390503B1 (en) | 2003-08-22 | 2008-06-24 | Barr Laboratories, Inc. | Ondansetron orally disintegrating tablets |
| CN2717851Y (zh) | 2004-05-14 | 2005-08-17 | 重庆康刻尔制药有限公司 | 一种药品包装板 |
| TWI482772B (zh) | 2006-08-21 | 2015-05-01 | Astrazeneca Ab | 適合口服且包含三唑并[4,5-d]嘧啶衍生物之組合物 |
| CN102058889A (zh) * | 2010-11-05 | 2011-05-18 | 王定豪 | 包含抗凝血类药物的分散片及其应用 |
| FR2968992B1 (fr) | 2010-12-16 | 2013-02-08 | Sanofi Aventis | Comprime pharmaceutique orodispersible a base de zolpidem |
| US20130160408A1 (en) | 2011-12-22 | 2013-06-27 | Gregor N. Neff | Blister Pack and Method |
| WO2013115171A1 (ja) | 2012-02-03 | 2013-08-08 | 旭化成ケミカルズ株式会社 | 苦味マスク顆粒含有口腔内崩壊錠 |
| CZ2012705A3 (cs) * | 2012-10-16 | 2014-04-23 | Zentiva, K.S. | Pevná orální farmaceutická formulace obsahující ticagrelor |
| CN103964066B (zh) * | 2013-02-06 | 2017-09-19 | 李和伟 | 一种冻干赋型制剂的包装装置 |
| WO2015110952A1 (en) | 2014-01-21 | 2015-07-30 | Wockhardt Limited | Solid oral pharmaceutical compositions comprising ticagrelor or salt thereof |
| CN104650091B (zh) * | 2014-01-24 | 2016-10-05 | 福州乾正药业有限公司 | 替格瑞洛的微粉化及其晶型，以及制备方法和药物应用 |
| EA201691582A1 (ru) * | 2014-02-07 | 2017-01-30 | Оспекс Фармасьютикалз, Инк. | Новые фармацевтические препараты |
-
2017
- 2017-04-20 CN CN201710898954.2A patent/CN107595789B/zh active Active
- 2017-04-20 ES ES17720055T patent/ES3014055T3/es active Active
- 2017-04-20 HR HRP20250204TT patent/HRP20250204T1/hr unknown
- 2017-04-20 PE PE2018002028A patent/PE20190372A1/es unknown
- 2017-04-20 IL IL262312A patent/IL262312B/en unknown
- 2017-04-20 EP EP24187449.4A patent/EP4417537A3/en active Pending
- 2017-04-20 SM SM20250081T patent/SMT202500081T1/it unknown
- 2017-04-20 EA EA201892150A patent/EA201892150A1/ru unknown
- 2017-04-20 EP EP17720055.7A patent/EP3445338B1/en active Active
- 2017-04-20 LT LTEPPCT/EP2017/059443T patent/LT3445338T/lt unknown
- 2017-04-20 US US16/095,090 patent/US10729655B2/en active Active
- 2017-04-20 RS RS20250181A patent/RS66536B1/sr unknown
- 2017-04-20 CN CN201780000516.8A patent/CN107530288B/zh active Active
- 2017-04-20 PL PL17720055.7T patent/PL3445338T3/pl unknown
- 2017-04-20 FI FIEP17720055.7T patent/FI3445338T3/fi active
- 2017-04-20 CN CN201710899077.0A patent/CN107595790B/zh active Active
- 2017-04-20 PT PT177200557T patent/PT3445338T/pt unknown
- 2017-04-20 DK DK17720055.7T patent/DK3445338T3/da active
- 2017-04-20 MA MA44720A patent/MA44720B1/fr unknown
- 2017-04-20 KR KR1020187033221A patent/KR102392347B1/ko active Active
- 2017-04-20 WO PCT/EP2017/059443 patent/WO2017182589A1/en not_active Ceased
- 2017-04-20 KR KR1020227013818A patent/KR102488486B1/ko active Active
- 2017-04-20 SG SG10202107682QA patent/SG10202107682QA/en unknown
- 2017-04-20 SG SG11201808996SA patent/SG11201808996SA/en unknown
- 2017-04-20 BR BR112018071440A patent/BR112018071440A2/pt not_active Application Discontinuation
- 2017-04-20 SI SI201731586T patent/SI3445338T1/sl unknown
- 2017-04-20 JP JP2018555237A patent/JP6960941B2/ja active Active
- 2017-04-20 HU HUE17720055A patent/HUE070095T2/hu unknown
- 2017-04-20 AU AU2017253367A patent/AU2017253367B2/en active Active
-
2018
- 2018-10-18 PH PH12018502226A patent/PH12018502226A1/en unknown
- 2018-11-19 CO CONC2018/0012431A patent/CO2018012431A2/es unknown
-
2020
- 2020-03-18 AU AU2020201930A patent/AU2020201930B2/en active Active
-
2021
- 2021-10-12 JP JP2021167539A patent/JP7254871B2/ja active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20250204T1 (hr) | Tablete za oralno otapanje | |
| AR118108A2 (es) | Formas cristalinas de un inhibidor de tirosina quinasa de bruton | |
| EP2490676B1 (en) | Pharmaceutical compositions of pde-5 inhibitors and dapoxetine | |
| AR084865A1 (es) | Preparacion de desintegracion rapida, comprimido dispersable por via oral | |
| FI2498756T4 (fi) | Neratinibimaleaatin tablettiformulaatiot | |
| JP2019516674A5 (enExample) | ||
| JP2015057451A5 (enExample) | ||
| WO2014064409A1 (en) | Pharmaceutical antiretroviral composition | |
| MX2015011896A (es) | Formulacion de liberacion sostenida de mosapride que proporciona efectos farmacologicos y clinicos con administracion una vez al dia. | |
| JP2014198723A5 (enExample) | ||
| WO2014184553A1 (en) | Pharmaceutical antiretroviral compositions | |
| JP2016540021A5 (enExample) | ||
| RU2012121185A (ru) | Фармацевтические композиции комбинаций ингибиторов дипептидилпептидазы-4 с пиоглитазоном | |
| JP2015038135A5 (enExample) | ||
| JP2017506624A5 (enExample) | ||
| JP2006512324A (ja) | 睡眠障害の治療のための短時間作用性催眠薬を含む放出修飾組成物 | |
| US20150104511A1 (en) | Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine | |
| RU2018136580A (ru) | Цитратная соль (s)-4-((s)-3-фтор-3-(2-(5,6,7,8-тетрагидро-1,8-нафтиридин-2-ил)этил)пирролидин-1-ил)-3-(3-(2-метоксиэтокси)фенил)бутановой кислоты | |
| CN105338970B (zh) | 包含他达拉非和坦洛新的药物胶囊复合制剂 | |
| AR100977A1 (es) | Formulación compuesta para la administración oral que comprende ezetimiba y rosuvastatina, y un proceso para su preparación | |
| JP2019508464A (ja) | クロピドグレル及びアスピリンを含む複合製剤 | |
| GT200900089A (es) | Composicion farmaceutica en forma de microesferas recubiertas para la liberacion modificada de un relajante muscular y un aine | |
| EP2714045A1 (en) | Pharmaceutical antiretroviral composition | |
| JP2019533672A5 (enExample) | ||
| JP2013203690A (ja) | 口腔内崩壊錠及びその製造方法 |